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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comcompared to those with LVEF>30%. Thirty-day all-cause mortality was not signiﬁ-
cant different between the two groups (11.1% vs 6.3%, p¼0.14, HR 1.81, 95% CI
0.81-4.06). Patients with LVEF 30% had a trend toward higher risk of 30-day
cardiac mortality (11.1% vs 5.3%, p¼0.06, HR 2.16, 95% CI 0.95-4.90), which
disappeared after multivariable adjustment (p¼0.22). In a prespeciﬁed subgroup
analysis restricted to patients with LVEF30%, patients with baseline mean trans-
valvular gradient < 40 mmHG (low-gradient) presented a non-signiﬁcant higher risk
of all-cause death (31.6% vs 12.0%, p¼0.14, HR 2.46, 95% CI 0.69-8.74) and of
cardiac death (23.7% vs 12.0%, p¼0.32, HR 1.90, 95% CI 0.51-7.03) as compared to
patients with mean transvalvular gradient 40 mmHg (high-gradient).
Conclusions: Baseline severe impairment of LVEF is not a predictor of increased
short-term and mid-term mortality after TAVI. Among patients with severe
impairment of left ventricular function, those with low transvalvular gradient
deserve a careful evaluation because of numerically higher mortality rates. Selected
patients with severe impairment of left ventricular function should not be denied
TAVI.
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Background: Aortic valve implantation without balloon predilation may facilitate the
procedure, reduce rapid pacing duration and may impact the stroke rate. For the self-
expandable CoreValve this strategy has been shown to be feasible and safe in small
studies. Whether direct aortic valve implantation is applicable to the balloon-
expandable Edwards SAPIEN 3 valve is unknown. is applicable to the balloon-
expandable Edwards SAPIEN 3 valve is unknown. The aim of the present study was
to evaluate the feasablity and safety of transfemoral implantion of the Edwards SA-
PIEN 3 aortic valve without balloon predilation.
Methods: Forty one consecutive patients with severe symptomatic aortic stenosis and
high surgical risk were prospectively enrolled to receive the Edwards SAPIEN 3 aortic
valve without predilation.
Results: Mean age of the patients was 83.2  5.9 years, 58 % were male. Successful
implantation without predilation was achieved in 95.1 % of patients. In 2 patients (4.8
%) the prosthesis could not cross the native aortic valve due to severe asymmetric
calciﬁcation and an aortic valve oriﬁce area (AOA) of 0.4 and 0.5 cm2, respectively.
After predilation was performed from the contralateral site, the valve could be suc-
cessfully implanted in both patients. Post-dilation was performed in one patient due to
moderate aortic regurgitation. The cardiovascular 30 day MACCE rate was 2.4 %,
total mortality was 9,7% , reasons for death were pneumonia (1pt), urosepsis (1pt),
and subarachnoidal bleeding (1pt).
Conclusions: Transfemoral implantation of the Edwards SAPIEN 3 aortic valve
without balloon predilation is feasable and safe in the majority of patients, limitations
are severe asymmetric valve calciﬁcation in combination with AOA of 0.5 cm2 or
less.
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Background: Reducing length of stay (LoS) in selected TAVR patients is both
safe and feasible, but its role in mitigating healthcare costs has not been fully
evaluated.
Methods: Using the Medicare Provider Analysis and Review File, we retrospectively
analyzed 4,464 Medicare patients who underwent transfemoral-TAVR and were
discharged alive in ﬁscal year 2012. Hospitalization cost and discharge disposition
were assessed for 5 LoS cohorts (Table 1). Multivariate regression modeling, based on
patient demographics, comorbidities, and complications, was used to derive anB212 JACC Vol 64/11/Suppl B j Sepadjusted mean cost for each cohort. The 2013 MedPAR ﬁles, available shortly, will
also be analyzed and incorporated prior to presentation.
Results: The unadjusted mean hospitalization cost of transfemoral-TAVR cases was
$61,130 and the mean LoS was 7.7 days. Compared to patients with a LoS of 6-7
days, short-stay patients (discharged on day 1-3) had an unadjusted cost difference of
-$8,216 (p< 0.0001) and an adjusted difference of -$6,036 (p< 0.0001). Importantly,
patients discharged earlier were less likely to require assistance at discharge (65% vs
42%, p< 0.0001). Temporal trends between 2012 and 2013 will also be analyzed.
Conclusions: Early discharge in selected patients can have meaningful cost savings at
a program level. Additionally, patients discharged early require less post-acute care
services than patients with longer stays, alleviating concerns that early discharge of
Medicare patients may be associated with higher societal costs. Efforts aimed at
optimized patient selection and peri-TAVR care with a view to reducing LoS are
warranted.
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Background: TAVI has gained signiﬁcant relevance in the treatment of inoperable or
high-risk patients with symptomatic aortic stenosis. Several risk scores have been
proposed to estimate the perioperative and long-term risk of patients undergoing
TAVI. However, assessment of individual risk remains difﬁcult. We thus aimed to
analyze whether biomarkers may improve risk stratiﬁcation.
Methods: We prospectively included 267 patients undergoing TAVI (using balloon-
expandable Edwards Sapien XT prostheses) at our institution from Feb. 2011 until
Dec. 2013. n¼260 patients were available for complete follow up. 56.2% were fe-
males, mean age was 81.9 years ( 6.8 years), 57.3% were treated via transfemoral,
28.1% transapical, 14.6% transaortic access. Biomarkers (hsTNT and NTproBNP) as
well as other parameters were measured a day before TAVI, 3 and 7 days post-pro-
cedure. 11.2% had severely reduced EF, and mean log. Euroscore (ES) was 26.3% (
17%). Median follow-up was 262 days (IQR 77-501d), the primary endpoint was
survival time; a total of 74 deaths (27.7%) occurred. 30d mortality was 6.0%. All
possible prognostic factors were analyzed by Cox regression analysis with backward
selection based on the likelihood ratio criteria.
Results: Median preprocedural hsTNT values were 28.4 pg/ml (IQR 16.2-46.1 pg/
ml). From all potential prognostic factors, preprocedural hsTNT (HR¼2.67 for upper
quartile vs. quartiles 1-3, CI 1.63-4.38, p< 0.001) and the log. ES (HR¼1.98, CI 1.2-
3.27 p¼0.006) emerged as independent prognostic parameters for adverse outcome. In
contrast, unimpaired renal function appeared to be protective (HR¼0.48, CI: 0.21-
1.06, p¼0.047). In addition, we also tested whether the VARC-2 cut-off for
myocardial damage (hsTNT peak value exceeding 15 as the upper reference limit,
210 pg/ml) was of prognostic relevance. At 72 h post-TAVI, n¼87 pts (37.5%) had
hsTNT levels 210 pg/ml. However, these pts did not reveal a signiﬁcant difference
in survival compared to pts with a hsTNT < 210 pg/ml at this timepoint.
Conclusions: In conclusion, elevated preprocedural hsTNT is an independent risk
predictor of all-cause death while periprocedural hsTNT elevation failed to exhibit
prognostic relevance.
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Background: The impact of preoperative mitral regurgitation on clinical outcome of
patients undergoing TAVI is controversial. This study is to assess the contribution of
mitral regurgitation to clinical outcomes after TAVI.
Methods: Data from Asian TAVI multicenter registry were pooled and analyzed. In
total, 185 patients with severe symptomatic aortic stenosis undergoing TAVI were
included. 16 patients (8.6%) had preoperative mitral regurgitation  moderate and the
study patients were divided into 2 groups according to preoperative mitral regurgi-
tation: group I (mitral regurgitation  mild) and group II (  moderate).
Results: Baseline LVEF and aortic valve area were smaller in Group II, but there were
no difference in other demographics including age, sex, diabetes, hypertension, pre-
vious PCI, previous CABG, peripheral artery disease, mean pressure gradient and
Logistic EuroSCORE. There was no difference in device success rate (79.7% vs.
81.3%; p > 0.99), however 30-day mortality was higher in group II (30-day mortality:
1.5% vs. 18.8%; Relative Risk, 12.53; 95% conﬁdence interval [CI], 2.31 – 98.84;tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMp ¼ 0.009). At 1-year, mortality rate was higher in group II (6.1% vs. 26.3%; hazard
ratio [HR], 4.46; 95% CI, 1.34 – 14.83: p ¼ 0.029). Multivariate Cox regression
analysis identiﬁed preoperative mitral regurgitation  moderate (HR, 5.35; 95% CI,
1.58 – 18.10; p ¼ 0.007) and body mass index (HR, 0.75; 95% CI, 0.60 – 0.94;
p ¼ 0.012) as independent predictors of mortality.
Conclusions: Preoperative mitral regurgitation  moderate was associated with
higher 30-day and 1-year mortality.TCT-726
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Background: Pulmonary hypertension (PHTN) is a major risk factor for patients
undergoing cardiac surgery as it associated with high peri- and post-operative mor-
tality. There is limited data on PHTN among patients who undergo transcatheter aortic
valve replacement (TAVR). This analysis sought to assess the prevalence and clinical
impact of PHTN of such patients.
Methods: Clinical data of patients with AS who underwent TAVR was retrospec-
tively analyzed. Patients were divided into two groups based on systolic pulmonary
artery pressure: 0-50 mmHg (No/Mild group) versus >50 mmHg (moderate/severe
group).
Results: A total of 415 patients were included. No/mild PHTN was present in 172
(41.5%) and moderate/severe PHTN in 243 (58.5%). The average age was 848 years
and 47% were male. Average STS score was 10.04.7. There were no signiﬁcant
differences between groups in baseline characteristics or in baseline echo, apart from
moderate/severe tricuspid regurgitation, which was more frequent among moderate/
severe PHTN patients (23% vs. 5.9%, p < 0.001) and average baseline pulmonary
pressure (6112 vs. 379, p < 0.001). Procedural and post-procedural complications
were similar. (Figure) Mortality at 30 days and 1-year follow up was signiﬁcantly
higher in the moderate/severe PHTN group (30 days 14.5% vs. 7.4%, p¼0.019, and 1
year 30.8% vs. 21.0%, p¼0.023).JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaConclusions: Patients with severe aortic stenosis and pulmonary hypertension, un-
dergoing TAVR may have some improvement in their PHTN and tricuspid regurgi-
tation indices. Nevertheless, this group has higher mortality rate and should subjected
ti intense monitoring and treatment
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Background: The repositionable and fully retrievable, CE-marked Lotus Valve is
designed to facilitate controlled, precise positioning and minimize paravalvular aortic
regurgitation. Results to 2 years post-implantation with Lotus have not yet been
reported.
Methods: REPRISE I is a prospective, single-arm, 3-center feasibility study designed
to assess acute safety and performance of the 23mm Lotus Valve in symptomatic
patients with calciﬁed aortic stenosis and high surgical risk.
Results: The Lotus Valve was implanted in 11 female patients (mean age 83.03.6
years; mean STS score 4.92.5%). All patients were considered high risk for surgery
due to frailty or associated comorbidities (gait speed 6s [9/11], grip strength 18kg
[7/11], and cognitive dysfunction [5/11; deﬁned as a score < 4 on the Mini-Cognitive
Assessment for Dementia]). Clinical procedural success was achieved in 9/11 and
partial resheathing/repositioning was successfully performed in 4 patients; no valves
required full retrieval. At 1 year, follow-up was 100% (11/11 patients). There were no
new VARC1 Safety Composite events, bleeding events, or new pacemaker implan-
tation between 30 days and 1 year. The safety composite remained 3/11 (2 patients
with non-valve-related disabling bleeding, 1 with major ischemic stroke and vascular
complication). Conduction disturbance requiring new permanent pacemaker implan-
tation remained at 4 patients; only 2 patients were pacemaker dependent at 1 year.
NYHA class was signiﬁcantly (P¼0.004) improved at 1 year with 5 (46%) patients in
Class I, and 6 (55%) in Class II. Signiﬁcant improvements in mean aortic gradient and
aortic valve area were sustained at 1 year (mean gradient 15.44.6mmHg; mean area
1.50.2cm2; P< 0.001 vs baseline for each). Core laboratory adjudicated paravalvular
aortic regurgitation was trace/trivial in 1 patient, mild in 1 patient, and absent in 8
patients at 1 year.
Conclusions: One-year feasibility results suggest that the Lotus Valve can be posi-
tioned accurately and successfully with virtually no aortic regurgitation and low
clinical event rates. Two-year outcomes from REPRISE I will be presented for the ﬁrst
time at TCT 2014.
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Background: The number of Transcatheter Aortic Valve Replacement (TAVR)
programs has increase in the US. However, the number of referrals to TAVR centers
for evaluation remains uncertain. We sought to describe the temporal changes of
treatment allocation after FDA approval of currently available transcatheter aortic
valves.
Methods: We retrospectively analyzed all patients who were referred to our center
between January 1, 2010, and July 31, 2013. The number of referrals were grouped
and analyzed by year with three distinct landmark time points. These landmark
points represent the approval of the two currently available transcatheter heart
valves.
Results: Following initial screening of 1051 patients, 18% (n¼192) patients under-
went TAVR, 34% (n¼357) balloon aortic valvuloplasty (BAV), 8% (n¼84) surgical
replacement (SAVR) and 40% (n¼418) medical therapy. Mean time from last
screening to TAVR was 26  47 days, and mean time from last screening to SAVR
was 10  15 days. As shown in Figure 1 the number of patients receiving TAVR and
SAVR has increased overtime in contrast to the number of patients treated with BAV
and medical therapy.lvular disease - Aortic: TAVR B213
